Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
The British Journal of Dermatology|July 17, 2016
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trialR Bissonnette, K A Papp, Y Poulin, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 16, 2019
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trialB E Elewski, C S Baker, J J Crowley, et al.The British Journal of Dermatology|July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)K B Gordon, R B Warren, A B Gottlieb, et al.Acta Dermato-Venereologica|July 20, 2002
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgarisW S Douglas, Y Poulin, J Decroix, et al.The British Journal of Dermatology|September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)C Paul, J Cather, M Gooderham, et al.The British Journal of Dermatology|October 14, 2014
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upR G Langley, M Lebwohl, G G Krueger, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2017
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisA Blauvelt, K A Papp, H Sofen, et al.The Journal of Dermatological Treatment|May 1, 2020
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trialsK B Gordon, K Reich, J J Crowley, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 3, 2021
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyondJ Beecker, K A Papp, J Dutz, et al.Pageof 5